Pomanda estimates the enterprise value of NAPP PHARMACEUTICALS LIMITED at £33.7m based on a Turnover of £35.5m and 0.95x industry multiple (adjusted for size and gross margin).
napp pharmaceuticals limitedEstimated Valuation
£13.8m
Pomanda estimates the enterprise value of NAPP PHARMACEUTICALS LIMITED at £13.8m based on an EBITDA of £1.4m and a 9.57x industry multiple (adjusted for size and gross margin).
napp pharmaceuticals limitedEstimated Valuation
£19.1m
Pomanda estimates the enterprise value of NAPP PHARMACEUTICALS LIMITED at £19.1m based on Net Assets of £10m and 1.92x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Napp Pharmaceuticals LimitedOverview
Napp Pharmaceuticals Limited is a live company located in cambridge, CB4 0GW with a Companies House number of 03690299. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in December 1998, it's largest shareholder is
napp pharmaceutical holdings ltd
with a 99.6% stake. Napp Pharmaceuticals Limited is a mature,
large sized company, Pomanda has estimated its turnover at
£35.5m with
declining
growth in recent years.
Pomanda's financial health check has awarded Napp Pharmaceuticals Limited a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 4 areas for improvement. Company Health Check FAQs
Health Rating4.5out of 5
4 Strong
3 Regular
4 Weak
Size
annual sales of £35.5m, make it larger than the average company (£24.4m)
£35.5m - Napp Pharmaceuticals Limited
£24.4m - Industry AVG
Growth
3 year (CAGR) sales growth of -34%, show it is growing at a slower rate (5.3%)
-34% - Napp Pharmaceuticals Limited
5.3% - Industry AVG
Production
with a gross margin of 34.2%, this company has a comparable cost of product (29.5%)
34.2% - Napp Pharmaceuticals Limited
29.5% - Industry AVG
Profitability
an operating margin of 4.1% make it as profitable than the average company (4.1%)
4.1% - Napp Pharmaceuticals Limited
4.1% - Industry AVG
Employees
with 36 employees, this is similar to the industry average (36)
36 - Napp Pharmaceuticals Limited
36 - Industry AVG
Pay Structure
on an average salary of £151.3k, the company has a higher pay structure (£81.2k)
£151.3k - Napp Pharmaceuticals Limited
£81.2k - Industry AVG
Efficiency
resulting in sales per employee of £986.6k, this is more efficient (£656k)
£986.6k - Napp Pharmaceuticals Limited
£656k - Industry AVG
Debtor Days
it gets paid by customers after 3 days, this is earlier than average (57 days)
3 days - Napp Pharmaceuticals Limited
57 days - Industry AVG
Creditor Days
its suppliers are paid after 23 days, this is quicker than average (29 days)
23 days - Napp Pharmaceuticals Limited
29 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Napp Pharmaceuticals Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities
for 0 weeks, this is less cash available to meet short term requirements (11 weeks)
0 weeks - Napp Pharmaceuticals Limited
11 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 43.7%, this is a lower level of debt than the average (54.4%)
43.7% - Napp Pharmaceuticals Limited
54.4% - Industry AVG
NAPP PHARMACEUTICALS LIMITED financials
EXPORT
Napp Pharmaceuticals Limited's latest turnover from December 2023 is £35.5 million and the company has net assets of £10 million. According to their latest financial statements, Napp Pharmaceuticals Limited has 36 employees and maintains cash reserves of £13 thousand as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Turnover
35,518,000
70,404,000
99,815,000
123,872,000
152,741,000
144,974,000
126,867,000
127,816,000
134,202,000
143,972,000
135,114,000
133,376,000
118,702,000
108,009,000
95,893,000
Other Income Or Grants
Cost Of Sales
23,366,000
55,855,000
80,018,000
86,746,000
107,720,000
102,311,000
87,402,000
91,545,000
94,733,000
105,311,000
99,749,000
92,666,000
78,857,000
71,922,000
64,265,000
Gross Profit
12,152,000
14,549,000
19,797,000
37,126,000
45,021,000
42,663,000
39,465,000
36,271,000
39,469,000
38,661,000
35,365,000
40,710,000
39,845,000
36,087,000
31,628,000
Admin Expenses
10,714,000
12,868,000
16,862,000
32,763,000
40,719,000
37,998,000
35,287,000
32,491,000
33,838,000
30,996,000
31,983,000
32,076,000
29,985,000
29,559,000
25,873,000
Operating Profit
1,438,000
1,681,000
2,935,000
4,363,000
4,302,000
4,665,000
4,178,000
3,780,000
5,631,000
7,665,000
3,382,000
8,634,000
9,860,000
6,528,000
5,755,000
Interest Payable
326,000
177,000
306,000
322,000
197,000
Interest Receivable
18,000
8,000
82,000
126,000
255,000
179,000
111,000
108,000
183,000
205,000
136,000
63,000
111,000
Pre-Tax Profit
1,456,000
1,689,000
3,017,000
4,489,000
4,568,000
4,350,000
3,806,000
3,834,000
5,574,000
7,699,000
3,565,000
8,839,000
9,690,000
6,269,000
5,669,000
Tax
-160,000
-340,000
-578,000
-1,037,000
-1,027,000
-1,000,000
-981,000
-945,000
-1,501,000
-1,673,000
-1,107,000
-2,326,000
-2,826,000
-2,046,000
-1,952,000
Profit After Tax
1,296,000
1,349,000
2,439,000
3,452,000
3,541,000
3,350,000
2,825,000
2,889,000
4,073,000
6,026,000
2,458,000
6,513,000
6,864,000
4,223,000
3,717,000
Dividends Paid
335,000
784,000
7,000,000
15,500,000
20,000,000
Retained Profit
961,000
565,000
2,439,000
3,452,000
3,541,000
-3,650,000
-12,675,000
2,889,000
4,073,000
-13,974,000
2,458,000
6,513,000
6,864,000
4,223,000
3,717,000
Employee Costs
5,445,000
5,474,000
9,285,000
17,679,000
18,515,000
16,095,000
14,615,000
14,213,000
18,928,000
16,014,000
16,291,000
15,004,000
15,608,000
18,412,000
17,941,000
Number Of Employees
36
49
68
170
196
190
176
173
227
216
222
212
236
274
302
EBITDA*
1,439,000
1,683,000
2,939,000
4,368,000
4,309,000
4,676,000
4,195,000
3,824,000
5,687,000
7,701,000
3,435,000
8,654,000
9,977,000
6,739,000
6,079,000
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Tangible Assets
349,000
1,000
3,000
7,000
12,000
12,000
16,000
624,000
945,000
922,000
123,000
164,000
179,000
506,000
883,000
Intangible Assets
Investments & Other
Debtors (Due After 1 year)
17,000
20,000
17,000
20,000
21,000
22,000
25,000
1,266,000
614,000
905,000
Total Fixed Assets
366,000
21,000
20,000
27,000
33,000
34,000
41,000
1,890,000
1,559,000
1,827,000
123,000
164,000
179,000
506,000
883,000
Stock & work in progress
Trade Debtors
307,000
6,785,000
10,394,000
13,253,000
31,997,000
40,225,000
30,441,000
35,949,000
39,181,000
36,152,000
30,796,000
28,716,000
25,520,000
23,769,000
20,724,000
Group Debtors
14,037,000
20,064,000
7,777,000
6,053,000
1,475,000
2,193,000
7,352,000
2,109,000
Misc Debtors
2,949,000
251,000
219,000
668,000
1,061,000
1,208,000
11,091,000
1,408,000
429,000
722,000
733,000
645,000
1,823,000
1,449,000
802,000
Cash
13,000
15,000
17,000
20,000
24,000
29,000
39,000
19,000
19,000
23,000
892,000
932,000
15,732,000
9,651,000
misc current assets
total current assets
17,306,000
27,115,000
18,407,000
19,994,000
33,082,000
41,462,000
41,571,000
38,832,000
39,629,000
36,893,000
33,745,000
37,605,000
30,384,000
40,950,000
31,177,000
total assets
17,672,000
27,136,000
18,427,000
20,021,000
33,115,000
41,496,000
41,612,000
40,722,000
41,188,000
38,720,000
33,868,000
37,769,000
30,563,000
41,456,000
32,060,000
Bank overdraft
Bank loan
Trade Creditors
1,506,000
1,632,000
2,730,000
1,733,000
1,784,000
1,051,000
1,629,000
1,303,000
824,000
848,000
1,148,000
2,060,000
1,785,000
2,270,000
1,058,000
Group/Directors Accounts
12,516,000
27,544,000
7,209,000
5,011,000
15,214,000
18,138,000
13,106,000
other short term finances
hp & lease commitments
39,000
244,000
364,000
other current liabilities
6,209,000
15,826,000
5,920,000
10,086,000
13,677,000
10,622,000
26,283,000
18,003,000
17,288,000
8,180,000
4,734,000
10,176,000
9,779,000
8,642,000
9,287,000
total current liabilities
7,715,000
17,458,000
8,650,000
11,819,000
27,977,000
39,217,000
35,121,000
19,306,000
23,123,000
24,242,000
5,882,000
12,236,000
11,603,000
29,294,000
23,815,000
loans
hp & lease commitments
66,000
327,000
Accruals and Deferred Income
other liabilities
provisions
89,000
81,000
278,000
55,000
60,000
45,000
total long term liabilities
89,000
81,000
278,000
7,785,000
3,491,000
4,741,000
55,000
60,000
66,000
372,000
total liabilities
7,715,000
17,547,000
8,731,000
12,097,000
27,977,000
39,217,000
35,121,000
27,091,000
26,614,000
28,983,000
5,937,000
12,296,000
11,603,000
29,360,000
24,187,000
net assets
9,957,000
9,589,000
9,696,000
7,924,000
5,138,000
2,279,000
6,491,000
13,631,000
14,574,000
9,737,000
27,931,000
25,473,000
18,960,000
12,096,000
7,873,000
total shareholders funds
9,957,000
9,589,000
9,696,000
7,924,000
5,138,000
2,279,000
6,491,000
13,631,000
14,574,000
9,737,000
27,931,000
25,473,000
18,960,000
12,096,000
7,873,000
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Operating Activities
Operating Profit
1,438,000
1,681,000
2,935,000
4,363,000
4,302,000
4,665,000
4,178,000
3,780,000
5,631,000
7,665,000
3,382,000
8,634,000
9,860,000
6,528,000
5,755,000
Depreciation
1,000
2,000
4,000
5,000
7,000
11,000
17,000
44,000
56,000
36,000
53,000
20,000
117,000
211,000
324,000
Amortisation
Tax
-160,000
-340,000
-578,000
-1,037,000
-1,027,000
-1,000,000
-981,000
-945,000
-1,501,000
-1,673,000
-1,107,000
-2,326,000
-2,826,000
-2,046,000
-1,952,000
Stock
Debtors
-9,810,000
8,713,000
-1,587,000
-13,085,000
-8,376,000
-102,000
1,459,000
-126,000
2,445,000
4,057,000
-2,991,000
7,261,000
4,234,000
3,692,000
21,526,000
Creditors
-126,000
-1,098,000
997,000
-51,000
733,000
-578,000
326,000
479,000
-24,000
-300,000
-912,000
275,000
-485,000
1,212,000
1,058,000
Accruals and Deferred Income
-9,617,000
9,906,000
-4,166,000
-3,591,000
3,055,000
-15,661,000
8,280,000
715,000
9,108,000
3,446,000
-5,442,000
397,000
1,137,000
-645,000
9,287,000
Deferred Taxes & Provisions
-89,000
8,000
-197,000
278,000
-55,000
-5,000
60,000
-45,000
45,000
Cash flow from operations
1,257,000
1,446,000
582,000
13,052,000
15,446,000
-12,461,000
10,361,000
4,199,000
10,825,000
5,062,000
-1,040,000
-201,000
3,569,000
1,523,000
-7,009,000
Investing Activities
capital expenditure
-349,000
-7,000
-7,000
591,000
277,000
-79,000
-835,000
-12,000
-5,000
210,000
166,000
-1,207,000
Change in Investments
cash flow from investments
-349,000
-7,000
-7,000
591,000
277,000
-79,000
-835,000
-12,000
-5,000
210,000
166,000
-1,207,000
Financing Activities
Bank loans
Group/Directors Accounts
-12,516,000
-15,028,000
20,335,000
7,209,000
-5,011,000
-10,203,000
15,214,000
-18,138,000
5,032,000
13,106,000
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
-39,000
-271,000
-381,000
691,000
other long term liabilities
share issue
-593,000
-672,000
-667,000
-666,000
-682,000
-562,000
5,535,000
-3,832,000
764,000
-4,220,000
4,156,000
interest
18,000
8,000
82,000
126,000
255,000
-326,000
-177,000
179,000
111,000
108,000
183,000
205,000
-170,000
-259,000
-86,000
cash flow from financing
-575,000
-664,000
-585,000
-13,056,000
-15,455,000
19,447,000
12,567,000
-8,664,000
-9,328,000
11,102,000
183,000
166,000
-18,579,000
4,392,000
17,867,000
cash and cash equivalents
cash
-2,000
-2,000
-3,000
-4,000
-5,000
-10,000
39,000
-19,000
-4,000
-869,000
-40,000
-14,800,000
6,081,000
9,651,000
overdraft
change in cash
-2,000
-2,000
-3,000
-4,000
-5,000
-10,000
39,000
-19,000
-4,000
-869,000
-40,000
-14,800,000
6,081,000
9,651,000
napp pharmaceuticals limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for napp pharmaceuticals limited. Get real-time insights into napp pharmaceuticals limited's credit score, group structure and payment trends.
Perform a competitor analysis for napp pharmaceuticals limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other large companies, companies in CB4 area or any other competitors across 12 key performance metrics.
napp pharmaceuticals limited Ownership
NAPP PHARMACEUTICALS LIMITED group structure
Napp Pharmaceuticals Limited has no subsidiary companies.
The largest shareholders in Napp Pharmaceuticals Limited include Napp Pharmaceutical Holdings Ltd and Pacific Moon Corp.
napp pharmaceutical holdings ltd
99.6%
pacific moon corp
0.2%
r napp holdings llc
0.1%
little menlo llc
0.1%
napp pharmaceuticals limited directors
Napp Pharmaceuticals Limited currently has 3 directors.
The longest serving directors include
Mr Bryan Lea (Jan 2003) and
Mr Stephen Jamieson (Feb 2019).
unit 191 cambridge science park, milton road, cambridge, CB4 0GW
Bank
LLOYDS TSB BANK PLC
Legal Advisor
-
napp pharmaceuticals limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to napp pharmaceuticals limited. Currently there are 0 open charges and 1 have been satisfied in the past.
napp pharmaceuticals limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for NAPP PHARMACEUTICALS LIMITED. This can take several minutes, an email will notify you when this has completed.
napp pharmaceuticals limitedCompanies House Filings - See Documents
